Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | CA2 | P00918 | 4/20 | 0.65 |
| ▸ | CA7 | P43166 | 4/20 | 0.65 |
| ▸ | CA9 | Q16790 | 4/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | DBH | P09172 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | TOP1 | P11387 | 3/20 | 0.54 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557106 | 1.00 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1758192 | 0.81 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1599733 | 0.81 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL39435 | 0.79 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL29350008 | 0.79 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL27815804 | 0.79 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL30030432 | 0.79 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL23495982 | 0.77 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| SCHEMBL144106 | 0.77 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL9491440 | 0.77 | CA12 (0.95) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | claimed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | claimed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | claimed |
| US-6783913-B2 | POLYMERIC ACETAL RESIN CONTAINS UNITS (A), (B), (C), (D), AND (E). UNIT (A) IS A VINYL ALCOHOL UNIT. UNIT; (B) IS A POLYVINYL ACETAL UNIT CONTAINING AN R GROUP, WHERE R IS HYDROGEN, AN ALIPHATIC GROUP, AN AROMATIC GROUP, OR AN | KODAK POLYCHROME GRAPHICS LLC | 2004-08-31 | — | — | US | claimed |
| US-20030198887-A1 | Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing | EASTMAN KODAK COMPANY | 2003-10-23 | — | — | US | claimed |
| EP-1350801-A1 | Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing | Kodak Polychrome Graphics GmbH (DE) | 2003-10-08 | — | — | EP | claimed |
| CN-111909101-B | EGFR kinase inhibitor and application thereof in preparation of anti-cancer drugs | 浙江大学 | 2022-07-19 | — | — | CN | disclosed |
| US-10918683-B2 | Methods to reduce fat accumulation and oxidative damage in liver using green mango extracts and compounds obtained therefrom | TCI CO., LTD. (TW) | 2021-02-16 | — | — | US | disclosed |
| WO-2020228635-A1 | EGFR KINASE INHIBITOR AND APPLICATION THEREOF IN PREPARING ANTI-CANCER DRUG | 浙江大学 | 2020-11-19 | — | — | WO | disclosed |
| CN-111909101-A | EGFR kinase inhibitor and application thereof in preparation of anti-cancer drugs | 浙江大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-108294957-A | The gear division resin adhesive of the amide derivatives of polyphenol containing unsaturated fatty acid | 成都交大麦迪克科技有限公司 | 2018-07-20 | — | — | CN | disclosed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-8029815-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L | 2011-10-04 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | ELFORD HOWARD L | 2008-02-28 | — | — | US | disclosed |
| EP-1744761-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | Molecules for Health, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005115405-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | MOLECULES FOR HEALTH, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6248782-B1 | ADMINISTERING ENZYME INHIBITOR | ELFORD HOWARD L (US) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA12 4523/4885CA1 2703/4885CA2 3757/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA12 4523/4885CA1 2703/4885CA2 3757/4885 |
| US-10918683-B2 | Methods to reduce fat accumulation and oxidative damage in liver using green mango extracts and compounds obtained therefrom | LIPC, GOT2, PNLIP | CA12 4167/4885CA1 4527/4885CA2 4220/4885 |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | CA12 4319/4885CA1 4730/4885CA2 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.